Sign in
Taking people in United StatesNo phase

How colored light may ease pain in people with long-lasting muscle and joint pain

Studies brain responses to colored light in adults with chronic musculoskeletal pain or fibromyalgia.

Key facts

Who runs it
University of North Carolina, Chapel Hill
Where
Chapel Hill, United StatesSee the site
Trial code
Registry title
Neural Mechanisms of Light Driven Analgesia
Status
Recruiting
People taking part
60 people, planned
Started
24 Feb 2026
Expected to end
31 Jan 2030
Type of study
Interventional
Treatments tested
  • S-cone modulating visual stimulus
  • Equal Energy White Visual Stimulus
  • Green light visual stimulus (S-OFF)
  • Evoked Pressure Pain Stimulus
Record updated
13 May 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic muscle and joint pain (including fibromyalgia) and healthy adults. It studies how colored light changes brain activity and pain during MRI scans. 2 people with congenital stationary night blindness and no chronic pain will also join.

Age
18 years or older
Sex
All sexes
Disease stage
People with pain must score ≥7 on the Widespread pain index (WPI) and ≥5 on the symptom severity scale (SSS), or 4-6 on the WPI and ≥9 on the SSS (2016 Fibromyalgia Questionnaire). Pain must have lasted 3 months or longer, be in 4 out of 5 body regions, and average ≥4 on a 0-10 scale over the past month.
Earlier treatment
No planned changes to medicines or treatment for the next 3 months.

Main reasons for not taking part

  • Eye or retina problems that harm vision, such as uveitis, cataracts or color-blindness
  • Sensitivity to or dislike of light
  • History of seizures
  • Pregnancy
  • Cannot have an MRI, for example metal implants, devices not safe for MRI, or fear of closed spaces

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Adults ≥18 years of age
  • Individuals who do not have any plans for medication or treatment changes for the next 3 months
  • Participants must be willing and able to undergo an MRI
  • Participants must not be claustrophobic
  • Participants must be alert and oriented and able to provide informed consent
  • Individuals must be able to speak and read English
  • To be eligible, participants must have a score of ≥7 on the Widespread pain index (WPI) and ≥5 on the symptom severity scale (SSS), or 4-6 on the WPI and ≥9 on the SSS in the 2016 Fibromyalgia Questionnaire
  • Pain symptoms must have been present for 3 months or longer
  • Pain must be present in 4 out of 5 body regions
  • Individuals enrolled will have an average pain severity ≥4 on the 0-10 NRS over the month prior to enrollment to recruit individuals with moderate to severe chronic MSP
  • -2 additional participants without chronic MSP will be recruited with diagnosed congenital stationary night blindness

Who cannot take part

  • Plans for analgesic treatment plan changes in next 3 months (surgery, analgesic medication changes, injections, pain procedures, etc)
  • Presence of retinal vision disorders or conditions resulting in vision impairment
  • Patient-reported photosensitivity, photophobia, or aversion (as may occur in autoimmune diseases such as systematic lupus erythematosus)
  • Disorders including uveitis, cataracts, color-blindness, history of seizure disorder
  • Prisoner Status
  • Pregnancy
  • Contraindications to MRI imaging. These include the presence of implanted/embedded ferromagnetic materials, implanted medical devices that are not MRI compatible, and claustrophobia

Where in United States

  • University of North Carolina at Chapel HillChapel Hill, United StatesContact: Matthew Mauck, MD, PhDTaking people

About the trial

What the trial wants to find out

The goal of this study will be to understand the biological mechanisms that are responsible to light-driven analgesia. Light presented to the retina has been shown to have pain relieving properties in pre-clinical and clinical studies. In this study the investigators will evaluate the functional connectivity between subcortical visual areas and non-image forming brain areas that are involved in pain sensation. The investigators will also evaluate how three colored light stimuli presented to the retina results in changes in whole brain evoked activation patterns in participants with chronic musculoskeletal pain and in healthy controls. The investigators will also assess while brain evoked activation patterns in response to a pressure pain stimulus in the presence of three light stimuli in individuals with chronic musculoskeletal pain and healthy controls.

The group in the trial

  • Light sequence during imagingTreatment being tested

    The sequence of stimulus presentation for resting state scans will be Equal Energy White (with luminance modulation) for 8 minutes then Static Green for 8 minutes, followed by an anatomical scan, then S-cone modulating stimuli for 8 minutes.

    Treatment: S-cone modulating visual stimulus, Equal Energy White Visual Stimulus, Green light visual stimulus (S-OFF), and Evoked Pressure Pain Stimulus

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Neural Mechanisms of Light Driven Analgesia
Plain-language title
How colored light may ease pain in people with long-lasting muscle and joint painGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Record updated
13 May 2026